GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akcea Therapeutics Inc (NAS:AKCA) » Definitions » Operating Margin %

Akcea Therapeutics (Akcea Therapeutics) Operating Margin % : -228.32% (As of Jun. 2020)


View and export this data going back to 2017. Start your Free Trial

What is Akcea Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Akcea Therapeutics's Operating Income for the three months ended in Jun. 2020 was $-51.1 Mil. Akcea Therapeutics's Revenue for the three months ended in Jun. 2020 was $22.4 Mil. Therefore, Akcea Therapeutics's Operating Margin % for the quarter that ended in Jun. 2020 was -228.32%.

The historical rank and industry rank for Akcea Therapeutics's Operating Margin % or its related term are showing as below:

AKCA' s Operating Margin % Range Over the Past 10 Years
Min: -355.83   Med: -277.57   Max: 7.79
Current: -13.56


AKCA's Operating Margin % is not ranked
in the Biotechnology industry.
Industry Median: -177.195 vs AKCA: -13.56

Akcea Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Akcea Therapeutics's Operating Income for the three months ended in Jun. 2020 was $-51.1 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2020 was $-45.8 Mil.


Akcea Therapeutics Operating Margin % Historical Data

The historical data trend for Akcea Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akcea Therapeutics Operating Margin % Chart

Akcea Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Operating Margin %
Get a 7-Day Free Trial - - -277.57 -355.83 7.79

Akcea Therapeutics Quarterly Data
Dec14 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -145.39 -158.02 29.97 -281.57 -228.32

Competitive Comparison of Akcea Therapeutics's Operating Margin %

For the Biotechnology subindustry, Akcea Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akcea Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akcea Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Akcea Therapeutics's Operating Margin % falls into.



Akcea Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Akcea Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2019 is calculated as

Operating Margin %=Operating Income (A: Dec. 2019 ) / Revenue (A: Dec. 2019 )
=38.074 / 488.543
=7.79 %

Akcea Therapeutics's Operating Margin % for the quarter that ended in Jun. 2020 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2020 ) / Revenue (Q: Jun. 2020 )
=-51.091 / 22.377
=-228.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akcea Therapeutics  (NAS:AKCA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Akcea Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Akcea Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Akcea Therapeutics (Akcea Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
22 Boston Wharf Road, 9th Floor, Boston, MA, USA, 02110
Akcea Therapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. Its most advanced drug, volanesorsen, has completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.
Executives
Michael J. Yang director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Joseph Iii Klein director C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Sandford D Smith director C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
B Lynne Parshall director 2855 GAZELLE COURT, CARLSBAD CA 92010
Joshua F. Patterson officer: General Counsel C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Damien Mcdevitt director, officer: Chief Executive Officer C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Alex G. Howarth officer: Chief Operating Officer C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Kyle Jenne officer: Chief Commercial Officer C/O AKCEA THERAPEUTICS, INC. 22 BOSTON WHARF ROAD, 9TH FLOOR BOSTON MA 02210
William T. Andrews officer: Chief Medical Officer ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Michael Dennis Price officer: Chief Financial Officer
Elaine Hochberg director C/O AKCEA THERAPAEUTICS 55 CAMBRIDGE PKWY, STE 100 CAMBRIDGE MA 02142
Isis Pharmaceuticals Inc 10 percent owner 2855 GAZELLE COURT, CARLSBAD CA 92010
Michael F Maclean officer: Chief Financial Officer 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Paula Soteropoulos director, officer: Chief Executive Officer 49 WINONA STREET, PEABODY MA 01960